Board of Directors

Mr. Gerald Lieberman - Chairman of the Board

Mr. Lieberman has served as a member of the Board of Directors since 2014. From 2000 until 2009, Mr. Lieberman was an executive at AllianceBernstein L.P. There, he was elected chief operating officer and a director in November 2003 and added the title of president in November 2004. Prior to that, Mr. Lieberman was senior vice president for finance and administration at Sanford C. Bernstein & Co., Inc. He has also held senior roles at Fidelity Investments and Citicorp. Mr. Lieberman currently serves on the board of Teva Pharmaceutical Industries Ltd. and serves as a special advisor at Reverence Capital Partners, a private investment firm focused on the middle-market financial services industry. Mr. Lieberman earned a B.S. from the University of Connecticut and attended New York University’s Graduate School of Business Administration. He is a certified public accountant, and a trustee of the University of Connecticut Foundation, Inc., where he is chairman of the finance committee and a member of the investment and executive committees.

Dr. Roger Garceau

Dr. Garceau has more than 30 years of broad pharmaceutical industry experience and has served as a director since March 2016 and as our Chief Development Advisor since December 2016. Prior to joining Entera, Dr. Garceau served as Chief Medical Officer and Executive Vice President of NPS Pharmaceuticals, Inc. since December 2008 and January 2013 respectively, until February 2015, when NPS Pharmaceuticals was acquired by Shire plc. Previously, Dr. Garceau has also served in several managerial positions with NPS Pharmaceuticals, Inc., Sanofi-aventis and Pharmacia Corporation. Dr Garceau has been a non-executive director of Enterome SA since December 2016. He is a board-certified pediatrician and is a Fellow of the American Academy of Pediatrics. Dr. Garceau holds B.S. in Biology from Fairfield University in Fairfield, Connecticut and an M.D. from the University of Massachusetts Medical School.

Miranda J. Toledano

Miranda J. Toledano is a partner at Fund7, a newly formed private equity firm and serves as Chief Financial Officer of TRIGR Therapeutics, a clinical stage immuno-oncology company focused on bispecific antibodies. Previously, Ms. Toledano served on the executive management team of Sorrento Therapeutics as EVP Corporate Development from September 2016 until August 2017. From 2012 to 2016, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed equity capital market transactions totaling over $4 billion in aggregate value. Prior to joining MLV, from 2004 until 2010, Ms. Toledano served in the investment group of Royalty Pharma, a leading investment firm with over $15 billion in biotherapeutic royalty assets. From 1998 to 2003, Ms. Toledano led the Life Sciences Corporate Finance group at Ernst & Young (Israel). Ms. Toledano holds a BA in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.

Mr. Zeev Bronfeld

Mr. Bronfeld has served as a member of our board of directors since 2010 and as chairman of our board of directors since September 2014 and until November 2016. Mr. Bronfeld has vast experience in the management and value building of biotechnology companies. From 2010 through July 2014, he served as the chairman of the board of Protalix BioTherapeutics, Inc. (NYSE: PLX) and has been a director on its board since 2006. Mr. Bronfeld serves as chairman of the board of directors of D.N.A Biomedical Solutions Ltd. Mr. Bronfeld is also a director of several privately-held companies, including The Trendlines Group Ltd, Contipi Medical Ltd. and as chairman of the board of TransBiodiesel Ltd. Mr. Bronfeld holds a B.A in Economics from the Hebrew University of Jerusalem.

Mr. Yonatan Malca

Mr. Malca has served as a member of the Board of Directors since 2011. Mr. Malca currently serves as a CEO and Director of D.N.A Biomedical Solutions Ltd., one of our principal shareholders, a position he has held since 2010. Mr. Malca also serves as a director of Arko Holdings Ltd., an Israeli public company. Mr. Malca also serves on the board of directors of a number of private companies, including as chairman of the board of directors of Cardioart Technologies LTD, a medical device company. Mr. Malca received a B.A. and an M.A. from Bar Ilan University.

Dr. Phillip Schwartz

Dr. Schwartz has more than twenty years of biotech and pharmaceutical industry experience. He has served as CEO and director of the board of director of Entera since its inception in September 2010. Previously he has held multiple positions in medical affairs, business development and clinical trial development at Serono and was served as manager of clinical affairs at Endo Pharmaceuticals. He has also consulted privately for more than 20 large biotech and pharmaceutical companies and a number of venture capital firms. Dr Schwartz has multiple publications in tier one peer reviewed journals and has presented papers at numerous international conferences. Dr. Schwartz completed his BA in psychology and architecture at Columbia University. He then studied and worked in neurobiology with Nobel Laureate Professor Torsten Wiesel of the Rockefeller University. After completing his project, Dr. Schwartz studied immunology with Professor Irun Cohen at the Weizmann Institute, receiving his MSc. in 1991. In 1997 Dr. Schwartz received his Ph.D. in neurobiology/development/oncology from Harvard Medical School.

Faith L. Charles

Faith L. Charles is a partner in the Corporate Transactions and Securities Practice, and the chair of the Life Sciences Group at Thompson Hine, LLP., since 2010. Since 2016, Ms. Charles serves as a member of the board of AgilVax Inc., a private biotechnology company focused on cancer immunotherapies and targeted infectious vaccines, and as a member of the board of Gilda's Club New York City, an organization that provides medical, emotional and support services to cancer patients and their families. Since September 2018, Ms. Charles serves as a member of the board of Sandstone Diagnostics, Inc., a private technology and healthcare company focused on using centrifugal testing to improve healthcare. Ms. Charles also serves as Chair and Co- Founder of Metro NY Women in Bio, an organization of professionals committed to promoting careers, leadership and entrepreneurship for women in the life sciences industry, since 2013. From 2000 until 2010, Ms. Charles served as partner at Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C. Prior to that, starting in 1986, Ms. Charles served as partner and associate at other law firms, where she focused on capital markets, licensing and other strategic collaborations and mergers and acquisitions for emerging and public companies. Ms. Charles holds a J.D degree from The George Washington University Law School and a B.A. in Psychology from Barnard College, Columbia University. Ms. Charles is also a graduate of Women in Bio's Boardroom Ready Program, an Executive Education Program taught by The George Washington University School of Business.